

Patient Name: MRS. SREELEKHA

Age / Gender: 49 years / Female

Patient ID: 89332

Referral: MediWheel

Collection Time : Mar 26, 2022, 09:29 a.m. **Reporting Time :** Mar 26, 2022, 01:22 p.m.

Sample ID:

Test Description	Value(s)	Reference Range	
COMPLETE BLOOD COUNT (CBC)			
Hemoglobin (Hb)	12.3	12.0 - 15.0	gm/dL
Erythrocyte (RBC) Count	4.39	3.8 - 4.8	mil/cu.mm
Packed Cell Volume (PCV)	37.5	36 - 46	%
Mean Cell Volume (MCV)	85.42	83 - 101	fL
Mean Cell Haemoglobin (MCH)	28.02	27 - 32	pg
Mean Corpuscular Hb Concn. (MCHC)	32.80	31.5 - 34.5	g/dL
Red Cell Distribution Width (RDW)	14.5	11.6 - 14.0	%
Total Leucocytes (WBC) Count	7800	4000-10000	cell/cu.mm
Neutrophils	63	40 - 80	%
Lymphocytes	27	20 - 40	%
Monocytes	6	2 - 10	%
Eosinophils	4	1 - 6	%
Basophils	0	1-2	%
Absolute Neutrophil Count	4914	2000 - 7000	/c.mm
Absolute Lymphocyte Count	2106	1000 - 3000	/c.mm
Absolute Monocyte Count	468	200 - 1000	/c.mm
Absolute Eosinophil Count	312	20 - 500	/c.mm
Absolute Basophils Count	0	20 - 100	/c.mm
Platelet Count	233	150 - 410	10^3/ul
Mean Platelet Volume (MPV)	9.7	7.2 - 11.7	fL
PCT	0.23	0.2 - 0.5	%
PDW	10.0	9.0 - 17.0	%
ESR	22.0	12.0 - 15.0	mm/hr

END OF REPORT

DR.UMA SAROJINI .K MBBS.,DCP.,





Patient Name: MRS. SREELEKHA

Age / Gender: 49 years / Female

Patient ID: 89332

Referral: MediWheel

Collection Time : Mar 26, 2022, 09:29 a.m. **Reporting Time :** Mar 26, 2022, 01:22 p.m.

Sample ID:

001008522

Test Description Value(s) Reference Range

URINE COMPLETE ANALYSIS,

Physical Examination

Quantity 35 - ml

Colour Pale Yellow Pale yellow/Yellow

Appearance Clear Clear

 Specific Gravity
 1.010
 1.005-1.025

 pH
 6.0
 5.0 - 8.0

 Deposit
 Present
 Absent

Chemical Examination

Protein Absent Absent Sugar Absent Absent **Ketones** Absent Absent **Bile Salt** Absent Absent **Bile Pigment** Absent Absent Urobilinogen Normal Normal

Microscopic Examination (/hpf)

Pus Cell Upto 5 1-2 1-2 **Epithelial Cells** Upto 5 **Red Blood Cells** Absent Absent Casts Absent Absent Crystals Absent Absent **Amorphous Deposit** Absent Absent **Yeast Cells** Absent Absent **Bacteria** Absent Absent Other findings Not seen Not seen







Patient Name: MRS. SREELEKHA

Age / Gender: 49 years / Female

Patient ID: 89332

Referral: MediWheel

Collection Time : Mar 26, 2022, 09:29 a.m. **Reporting Time :** Mar 26, 2022, 01:22 p.m.

Sample ID:

Reference Range

001008522

Test Description Value(s)

END OF REPORT

DR.UMA SAROJINI .K MBBS.,DCP.,





Patient Name: MRS. SREELEKHA

Age / Gender: 49 years / Female

Patient ID: 89332

Referral: MediWheel

Collection Time : Mar 26, 2022, 09:29 a.m. **Reporting Time :** Mar 26, 2022, 01:22 p.m.

Sample ID:

Test Description Value(s) Reference Range

BLOOD GROUP & RH TYPING

Blood Group (ABO typing)

Method : Manual-Hemagglutination

RhD Factor (Rh Typing)

Method : Manual hemagglutination

"A"

Positive

END OF REPORT

DR.UMA SAROJINI .K MBBS.,DCP.,





Patient Name: MRS. SREELEKHA

Age / Gender: 49 years / Female

Patient ID: 89332

Referral: MediWheel

Collection Time : Mar 26, 2022, 09:29 a.m. **Reporting Time :** Mar 26, 2022, 01:22 p.m.

Sample ID:

			001000022
Test Description	Value(s)	Reference Range	
Glycosylated HbA1c			
HbA1c (GLYCOSYLATED HEMOGLOBIN),	6.0		%
BLOOD			
Method : (HPLC, NGSP certified)			
Estimated Average Glucose :	125.50	-	mg/dL
Interpretation			
As per American Diabetes Association (ADA)			
Reference Group	HbA1c in %		
Non diabetic adults >=18 years	<5.7		
At risk (Prediabetes)	5.7 - 6.4		
Diagnosing Diabetes	>= 6.5		
	Age > 19 years		
	Goal of therapy:	< 7.0	
Therapeutic goals for glycemic control	Action suggeste	d: > 8.0	
	Age < 19 years		
	Goal of therapy:	<7.5	

Note:

- Since HbA1c reflects long term fluctuations in the blood glucose concentration, a diabetic patient who is recently under good control may still have a high concentration of HbA1c. Converse is true for a diabetic previously under good control but now poorly controlled.
- 2. Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life expectancy and no significant cardiovascular disease. In patients with significant complications of diabetes, limited life expectancy or extensive co-morbid conditions, targeting a goal of < 7.0 % may not be appropriate.

Comments

HbA1c provides an index of average blood glucose levels over the past 8 - 12 weeks and is a much better indicator of long term glycemic control as compared to blood and urinary glucose determinations.

O O O O

Scan to Validate



Page 5 of 12



Patient Name: MRS. SREELEKHA

Age / Gender: 49 years / Female

Patient ID: 89332

Referral: MediWheel

Collection Time : Mar 26, 2022, 09:29 a.m. **Reporting Time :** Mar 26, 2022, 01:22 p.m.

Sample ID:

Test Description

Value(s)

Reference Range

ADA criteria for correlation between HbA1c & Mean plasma glucose levels.

HbA1c(%)	Mean Plasma Glucose (mg/dL)
6	126
7	154
8	183
9	212
10	240
11	269
12	298

END OF REPORT

DR.UMA SAROJINI .K MBBS.,DCP.,





Patient Name: MRS. SREELEKHA Referral: MediWheel

Age / Gender: 49 years / Female Collection Time: Mar 26, 2022, 09:29 a.m.

Patient ID : 89332 **Reporting Time :** Mar 26, 2022, 01:22 p.m.

Sample ID :

Test Description	Value(s)	Reference Range		
THYROID PROFILE TEST - TOTAL				
T3-Total	92.0	60 - 200	ng/dL	
T4-Total	10.4	4.52 - 12	ug/dL	
TSH-Ultrasensitive	4.93	0.32 - 5.5	uIU/mL	
Method : CLIA		First Trimester: 0.1-2.5		
		Second Trimester: 0.2-3.0		

Third trimester: 0.3-3.0

Interpretation

TSH	T3	T4	Suggested Interpretation for the Thyroid Function Tests Pattern
Raised	Within range	Within range	Raised Within Range Within Range .Isolated High TSHespecially in the range of 4.7 to 15 m1U/m1 is commonly associated with Physiological & Biological TSH Variability. Subclinical Autoimmune Hypothyroidism.Intermittent 14 therapy for hypothyroidism .Recovery phase after Non-Thyroidal illness"
Raised	Decreased	Decreased	Chronic Autoimmune Thyroiditis Post thyroidectomy,Post radioiodine Hypothyroid phase of transient thyroiditis"
Raised or within range	Raised	Raised or within range	Interfering antibodies to thyroid hormones (anti-TPO antibodies)Intermittent 14 therapy or T4 overdose •Drug interference- Amiodarone, Heparin,Beta blockers,steroids, anti-epileptics.
Decreased	Raised or within range	Raised or within range	Isolated Low TSH -especially in the range of 0.1 to 0.4 often seen in elderly & Range Range associated with Non-Thyroidal illness .Subclinical Hyperthyroidism .Thyroxine ingestion'
Decreased	Decreased	Decreased	Central Hypothyroidism .Non-Thyroidal illness .Recent treatment for Hyperthyroidism (TSH remains suppressed)"
Decreased	Raised	Raised	Primary Hyperthyroidism (Graves' disease).Multinodular goitre, Toxic nodule •Transient thyroiditis:Postpartum, Silent (lymphocytic), Postviral (granulomatous,subacute, DeQuervain's),Gestational thyrotoxicosis with hyperemesis gravidarum"
Decreased Within Rang	Raised	Within range	T3 toxicosis •Non-Thyroidal illness
Within range	Decreased	Within range	Isolated Low T3-often seen in elderly & associated Non-Thyroidal illness In elderly the drop in 13 level can be upto 25%.

END OF REPORT

DR.UMA SAROJINI .K MBBS.,DCP.,





Patient Name: MRS. SREELEKHA

Age / Gender: 49 years / Female

Patient ID: 89332

Referral: MediWheel

Collection Time : Mar 26, 2022, 09:29 a.m. **Reporting Time :** Mar 26, 2022, 01:22 p.m.

Sample ID:

Test Description	Value(s)	Reference Range	
LIPID PROFILE			
Cholesterol-Total Method : Spectrophotometry	223.0	Desirable level < 200 Borderline High 200-239 High >or = 240	mg/dL
Triglycerides Method : Serum, Enzymatic, endpoint	121.0	Normal: < 150 Borderline High: 150-199 High: 200-499 Very High: >= 500	mg/dL
HDL Cholesterol Method : Serum, Direct measure-PEG	45.0	Normal: > 40 Major Risk for Heart: < 40	mg/dL
LDL Cholesterol Method : Enzymatic selective protection	153.80	Optimal < 100 Near / Above Optimal 100-129 Borderline High 130-159 High 160-189 Very High >or = 190	mg/dL
VLDL Cholesterol Method : Serum, Enzymatic	24.20	6 - 38	mg/dL
CHOL/HDL Ratio Method : Serum, Enzymatic	4.96	3.5 - 5.0	
LDL/HDL Ratio Method : Serum, Enzymatic Note:	3.42	2.5 - 3.5	
8-10 hours fasting sample is required.			

END OF REPORT

A SAROJINI .K MBBS.,DCP.,





Patient Name: MRS. SREELEKHA

Age / Gender: 49 years / Female

Patient ID: 89332

Referral : MediWheel

Collection Time : Mar 26, 2022, 09:29 a.m. **Reporting Time :** Mar 26, 2022, 01:22 p.m.

Sample ID:

est Description Value(s) Reference Range	
ENAL PROFILE	
rea 15.0 15-36	mg/dL
Method: Uricase	
ood Urea Nitrogen-BUN 7.00 7 - 17	mg/dL
Method : Serum, Urease	
reatinine 0.58 0.52-1.25	mg/dL
Method : Serum, Jaffe	
ric Acid 5.7 2.5 - 6.2	mg/dL
Method : Serum, Uricase	
emark:	
blood, Urea is usually reported as BUN and expressed in mg/dl. BUN mass units can be conve	erted to urea mass units by

In blood, Urea is usually reported as BUN and expressed in mg/dl. BUN mass units can be converted to urea mass units by multiplying by 2.14.

END OF REPORT

DR.UMA SAROJINI .K MBBS.,DCP.,





Patient Name: MRS. SREELEKHA

Age / Gender: 49 years / Female

Patient ID: 89332

Referral : MediWheel

Collection Time : Mar 26, 2022, 09:29 a.m. **Reporting Time :** Mar 26, 2022, 01:22 p.m.

Sample ID:

Test Description	Value(s)	Reference Range	
LIVER FUNCTION TEST			
Total Protein	8.2	6.3 - 8.2	g/dL
Method : Serum, Biuret, reagent blank end point			
Albumin	3.7	3.5 - 5.0	g/dL
Method : Serum, Bromocresol green			
Globulin	4.50	1.8 - 3.6	g/dL
Method : Serum, EIA			
A/G Ratio	0.82	1.2 - 2.2	
Method : Serum, EIA			
Bilirubin - Total	0.4	0.2 - 1.3	mg/dL
Method : Serum, Jendrassik Grof			
Bilirubin - Direct	0.1	< 0.3	mg/dL
Method : Serum, Diazotization			
Bilirubin - Indirect	0.3	0.0 - 1.1	mg/dL
Method : Serum, Calculated			
SGOT	15.0	14-36	U/L
Method : Serum, UV with P5P, IFCC 37 degree			
SGPT	28.0	< 52	U/L
Method : Serum, UV with P5P, IFCC 37 degree			
Alkaline Phosphatase	80.0	38 - 126	U/L
Method : PNPP-AMP Buffer/Kinetic			
GGT-Gamma Glutamyl Transpeptidae Method : Serum, G-glutamyl-carboxy-nitoanilide	22.0	< 43	U/L

END OF REPORT







Patient Name: MRS. SREELEKHA

Age / Gender: 49 years / Female

Patient ID: 89332

Referral: MediWheel

Collection Time : Mar 26, 2022, 09:29 a.m. **Reporting Time :** Mar 26, 2022, 01:22 p.m.

Sample ID:

Test Description	Value(s)	Reference Range	
GLUCOSE (F)			
Glucose fasting Method : GOD-POD	94.0	Normal: 70 - 120	mg/dL

END OF REPORT

DR.UMA SAROJINI .K MBBS.,DCP.,





Patient Name: MRS. SREELEKHA

Age / Gender: 49 years / Female

Patient ID: 89332

Referral: MediWheel

Collection Time : Mar 26, 2022, 09:29 a.m. **Reporting Time :** Mar 26, 2022, 01:22 p.m.

Sample ID:

Test Description	Value(s)	Reference Range	
GLUCOSE (PP)			
Blood Glucose-Post Prandial Method : GOD-POD	117	80- 140	mg/dL

END OF REPORT

DR.UMA SAROJINI .K MBBS.,DCP.,

